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Abstract
Purpose Prior studies have suggested that 18F-FDG PET/CT
can help characterize adrenal lesions and differentiate adrenal
metastases from benign lesions. The aim of this study was to
assess the value of 18F-FDG PET/CT for the differentiation of
malignant from benign adrenal lesions.
Methods This retrospective study included 85 patients
(47 men and 38 women, age 63.8±10.8 years) who had
undergone 18F-FDG PET/CT (60 min after injection
300 – 370 MBq 18F-FDG; Biograph 64 scanner) for evalua-
tion of 102 nonsecreting adrenal masses. For semiquantitative
analysis, the maximum standardized uptake value (SUVmax),
adrenal to liver (T/L) SUVmax ratio, mean CT attenuation
value and tumour diameter were measured in all lesions and
compared with the pathological findings.
Results Malignant adrenal tumours (68 % of evaluated
tumours) had a significantly higher mean SUVmax (13.0±
7.1 vs. 3.7±3.0), a higher T/L SUVmax ratio (4.2±2.6 vs.
1.0±0.9), a higher CT attenuation value (31.9±16. 7 HU vs.
0.2±25.8 HU) and a greater diameter (43.6±23.7 mm vs.
25.6±13.3 mm) than benign lesions. The false-positive find-
ings were tuberculosis and benign phaeochromocytoma.
Based on ROC analysis, a T/L SUVmax ratio >1.53, an
adrenal SUVmax >5.2, an attenuation value >24 HU and a
tumour diameter >30 mm were chosen as the optimal cut-off
values for differentiating malignant from benign tumours. The
areas under the ROC curves for the selected cut-off values
were 0.96, 0.96, 0.88 and 0.77, respectively. A multivariate
logistic regression model revealed that the T/L SUVmax ratio
was an independent prognostic factor for malignancy
(p<0.001); a CT attenuation value of >25 HU and a tumour
diameter >30 mm had no additional individual importance in
the diagnosis of malignancy.
Conclusion Using a T/L SUVmax ratio >1.53 and an adrenal
SUVmax >5.2 in 18F-FDG PET/CT led to high diagnostic
sensitivity, specificity and negative predictive value for char-
acterizing adrenal tumours. The diagnostic accuracies of the
two parameters were comparable, but T/L SUVmax ratio was
an independent predictor of malignancy.
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Introduction
Approximately 50 % of adrenal lesions in patients with a
primary known extraadrenal malignancy are metastatic. How-
ever, benign adrenal tumours may occur in the general popu-
lation and in patients with cancer. In oncological patients,
distinguishing benign from metastatic adrenal tumours is of-
ten critical in determining the stage of disease, in predicting
prognosis and in determining optimal management [1–3].
Conventional imaging methods used to characterize adrenal
lesions, such as unenhanced CT attenuation, enhancement
washout CT or chemical-shift MRI, have some limitations in
predicting malignancy, indicating the need for new imaging
technologies. 18F-FDG PET/CT offers the opportunity to as-
sess glucose cell metabolism that is reprogrammed toward
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increased glycolysis in many cancers [4, 5]. Metabolic imag-
ing with PET is not only complementary to imaging with
conventional modalities but also may be more sensitive be-
cause alterations in the metabolism of cancer cells may
precede gross anatomical changes [3, 6, 7]. On the other
hand, 18F-FDG accumulates not only in malignant adrenal
tumours but also in 5 – 10 % of benign tumours that mimic
metastasis and limit the specificity of 18F-FDG PET/CT im-
aging. In published studies, false-positive 18F-FDG PET/CT
findings mainly represent adrenal adenomas, benign
phaeochromocytomas, endothelial cysts, and inflammatory
and infectious lesions [8, 9].
Different algorithms for distinguishing benign from malig-
nant tumours with 18F-FDG PET/CT have been proposed.
The visual criteria seem to be subjective and inconsistent,
especially for borderline adrenal activity [3, 7, 10–14]. Recent
studies have shown that the adrenal to liver (T/L) maximum
standardized uptake value (SUVmax) ratio is a more accurate
and reliable parameter than SUVmean and SUVmax, but data
on the routine use of the T/L SUVmax ratio are still insuffi-
cient [5, 15, 16]. The aim of this study was to assess the value
of 18F-FDG PET/CT for differentiation of malignant from
benign adrenal lesions. We explored the possibility of further
improving the performance of 18F-FDG PET/CT using the
T/L ratio for characterization of adrenal tumours. The results
were expressed in relation to histology as the reference
method.
Materials and methods
We performed a retrospective analysis of preoperative 18F-
FDG PET/CT scans obtained in 85 patients (47 men and 38
women; mean age 63.8±10.8 years, range 33 – 86 years) with
nonsecreting unilateral or bilateral adrenal masses identified
on CT.
The examinations were performed from January 2009 to
December 2012 in the Nuclear Department of the Medical
University ofWarsaw.Written informed consent was obtained
from all patients. Within 3 months of PET/CT imaging, all
patients underwent adrenalectomy (68 unilateral and 17
bilateral). Of the 85 patients, 41 had histopathologically
proven malignancies, as follows: lung cancer (10), colorectal
cancer (20), larynx carcinoma (2), breast cancer (6), cervix
cancer (2) and melanoma (1). The remaining 44 patients had a
suspected cancer with adrenal metastases.
PET/CT protocol
The patients fasted for at least 6 h before the examination and
blood glucose measurements were obtained in all patients
before the administration of 18F-FDG. Blood glucose levels
in all patients were less than 150 mg/dL (8.33 mmol/L). The
PET/CT examinations were performed 60 min after intrave-
nous injection of 300 to 370 MBq 18F-FDG from the skull
base to the upper thighs on a Biograph 64 TruePoint PET/CT
scanner (Siemens Medical Solutions, Knoxville, TN) using
three-dimensional mode. All patients were requested to drink
1.5 L of water for hydration and empty their bladder before the
PET/CT examination. Patients were positioned supine with
their arms raised according to standard CT practice. Initially,
low-dose CTscans were performed using a 64-detector helical
CT scanner primarily for attenuation correction. A continuous
low-dose CT scan was acquired in spiral mode using 120 kV,
170 mAs, slice thickness 2 mm, and pitch 0.8. No intravenous
or oral contrast agent was administered. The PET study was
performed immediately after the CT scan with the patient in
the same position covering an area identical to that covered by
the CT scan with 2 min per bed position (six or seven bed
positions depending on the size of the patient). PET image
data were reconstructed on a 168×168 matrix using the
ordered-subsets expectation maximization algorithm (two it-
erations, 14 subsets) and corrected for attenuation using the
CT data. The PET/CT images (half-body-attenuated and non-
attenuated PET, CT and fused images) were transferred to a
multimodal work station (Syngo (TrueD); Siemens Medical
Solutions) for analysis.
18F-FDG PET/CT and CT imaging data
Tumours were quantitatively assessed by a nuclear physician
with 5 years experience, and involved measuring SUVmax of
adrenal lesions and the T/L ratio. The SUVmax of 18F-FDG in
adrenal tumours was measured by drawing a region of interest
(ROI) that encompassed the central two-thirds of the adrenal
mass but did not include any peripheral areas to avoid partial
volume effects. The liver SUVmax values were determined
from a ROI drawn on a large homogeneous region of 18F-
FDG distribution within the right hepatic lobe at the same
axial level as the adrenal lesions, avoiding areas of large
vessels and parenchymal abnormalities. The T/L SUVmax
ratio was calculated with these results by dividing the adrenal
tumour SUVmax by the liver SUVmax value.
An experienced radiologist analysed theCTdata obtained from
PET/CT imaging. Native CT of the abdomen with a slice thick-
ness 5 mm was performed. Density is expressed in Hounsfield
units. The maximum diameter and mean unenhanced attenuation
(Hounsfield units) was calculated for each adrenal lesion.
Morphological examinations
Surgically resected specimens were fixed in 10 % neutral
buffered formalin and routinely processed for paraffin
embedding. The sections were cut to a thickness of
4 – 5 μm, stained with haematoxylin and eosin and examined
under a light microscope. Additionally in some cases
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immunohistochemical and histochemical studies were per-
formed. Pathologists with specific training and expertise in
adrenal pathology made all the morphological diagnoses.
Statistical methods
Parameters were characterized in terms of the mean (±SD). To
determine if there was a statistically significant difference
between malignant and benign tumours in terms of adrenal
SUVmax, T/L SUVmax ratio, attenuation value and tumour
diameter, the Mann-Whitney U test was used. A p value of
<0.05 was considered statistically significant.
We used univariate logistic regression models to assess predic-
tors of malignancy. The predictive power of the univariate logistic
regression models with continuous predictors was assessed by
receiver operating characteristic (ROC) analysis. ROC curves
indicating the ability to discriminate malignant from benign tu-
mours were plotted for adrenal SUVmax, T/L SUVmax ratio,
attenuation value and diameter, and optimal cut-off values were
chosen. ROC curves were compared based on their area under the
curve (AUC) as a summary measure of diagnostic accuracy.
Amultivariate logistic regression model was used with adrenal
SUVmax, T/L SUVmax ratio, CT attenuation value and tumour
diameter categorized according to the established cut-off values as
predictors to examine the independence of their relationship with
the presence of malignant lesions. Odds ratios (OR) and 95 %
confidence intervals (CI) for significant predictors are presented.A
5 % level of significance was used. Calculations were performed
using Stata v10 (Stata Statistical Software, release 10; Stata Cor-
poration, College Station, TX).
Results
The analysis included 102 unilateral or bilateral nonsecreting
adrenal tumours in 85 patients. Of the 85 patients, 17 had
bilateral adrenal lesions. Based on final pathology, of 70
benign adrenal tumours, 54 were adenomas (Fig. 1), 6
tuberculosis, 4 adrenal hyperplasia, 4 myelolipomas, and 2
phaeochromocytomas. Of 30 metastatic malignant tumours,
17 were from colon carcinoma, 10 from lung cancer (Fig. 2),
1 from melanoma, 1 from gastric cancer, and 1 adrenal lym-
phoma. There were two primary adrenal tumours: one adrenal
cortical carcinoma and a very rare entity: angiomyolipoma
with malignant potential (Fig. 3).
PET/CT in differentiating malignant from benign adrenal
lesions
Malignant adrenal tumours had a significantly higher mean
SUVmax (13.0±7.1 vs. 3.7±3.0; p<0.001), higher T/L
SUVmax ratio (4.2±2.6 vs. 1.0±0.9, p<0.001), higher CT
attenuation value (31.91±16. 7 HU vs. 0.2±25.8 HU,
p<0.001) and a greater diameter (43.6 mm±23.7 vs.
25.6 mm±13.3, p<0.001) than benign lesions. Six false-
positive results were observed in our series: four adrenal
tuberculosis and two benign phaeochromocytomas (Figs. 4
and 5). The benign lesions related to tuberculosis showed a
hypermetabolic pattern with T/L SUVmax ratios in the range
3.2 – 5.2. The 18F-FDG PET/CT scan showed intense uptake
of 18F-FDG in bilateral tumours in two patients (SUVmax
12.3 – 19) with T/L SUVmax ratios in the range 3.2 – 5.2 and
attenuation values in the range 32 – 37 HU, findings that
suggested malignancy. Interestingly, in the third patient with
bilateral adrenal tuberculosis, 18F-FDG PET/CT showed low-
er 18F-FDG uptake with SUVmax 3.2 and 4.8) and T/L
SUVmax ratios 0.9 and 1.3.
Significant predictors of malignancy in univariate logistic
regression analysis were: T/L SUVmax ratio (OR 3.7, 95 %
CI 2.26 – 5.99; p<0.001), adrenal SUVmax (OR 1.5, 95 % CI
1.25 – 1.71; p<0.001), attenuation value (OR 1.11, 95 % CI
1.06 – 1.16; p<0.001) and diameter (OR 1.06, 95 % CI
1.03 – 1.09; p<0.001). Based on the ROC analysis, an adrenal
SUVmax >5.2, T/L SUVmax ratio >1.53, attenuation
value >24 HU and tumour diameter >30 mm were chosen as
optimal cut-off values for differentiating malignant from be-
nign tumours (Figs. 6 and 7). The sensitivities and specificities
Fig. 1 18F-FDG PET/CT findings in a 55-year-old women with dissem-
inated metastasis from an unknown primary cancer (a CT image, b PET
image, c fused PET/CT image). The 18F-FDG PET/CT image shows low
18F-FDG uptake. The SUVmax of the enlarged right adrenal tumour was
2.3 and the attenuation value −11 HU; the liver SUVmax was 4. These
findings were consistent with a lipid-rich adenoma
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of these cut-off values were: 91 % (95 % CI 85 – 96 %) and
90 % (95 % CI 84 – 96 %), 94 % (95 % CI 89 – 99 %) and
91 % (95 % CI 86 – 97 %), 88 % (95 % CI 81 – 94 %) and
81% (95 %CI 74 – 89%), and 49% (95%CI 37 – 57%) and
89 % (95 % CI 82 – 98 %), respectively. The positive predic-
tive values (PPV) and negative predictive values (NPV) of
these cut-off values were: 81% (95%CI 73 – 88%) and 96%
(95 % CI 91 – 99.5 %), 83 % (95 % CI 76 – 91 %) and 97 %
(95 % CI 94 – 100 %), 65 % (95 % CI 56 – 75 %) and 79 %
(95 %CI 71 – 87%), and 68% (95%CI 59 – 77%) and 93%
(95 % CI 89 – 98 %), respectively.
A threshold value of 10 HU, generally accepted as the cut-
off value for differentiating adrenal tumours in our study
population, had a sensitivity of 94 % (95 % CI 89 – 99 %)
and specificity of 67 % (95 % CI 58 – 76 %). The PPV and
NPV for diagnosing adrenal adenoma were 57 % (95 % CI
47 – 66%) and 96% (95% CI 92 – 99.8%), respectively. The
AUC for adrenal SUVmax >5.2 was 0.96 (95 % CI
0.91 – 0.99 %), for T/L SUVmax ratio >1.53 was 0.96
(95 % CI 0.92 – 0.99 %, for attenuation value >24
HU was 0.81 (95 % CI 0.81 – 0.95 %), and for tumour
diameter >30 mm was 0.77 (95 % CI 0.66 – 0.87 %).
Based on the AUC, adrenal SUVmax and T/L SUVmax
ratio exhibited the highest and comparable diagnostic
performance for predicting malignant lesions. Tumour
diameter had the lowest AUC and was a poor predictor
of malignant disease.
Multivariate logistic regression model revealed that T/L
SUVmax ratio was an independent predictive factor for ma-
lignancy (OR 126.0, 95 % CI 10.5 – 1512.9, p<0.001). CT
attenuation value >24 HU and tumour diameter >30 mmwere
not independent predictive factors (p>0.1)
Discussion
18F-FDG PET/CT is a very useful tool for differentiating
benign from malignant adrenal lesions in patients with proven
malignancy with an overall sensitivity between 74 % and
100 %, and specificity between 69 % and 100 % [17]. How-
ever, many studies addressing this issue have been limited by
their retrospective design, small sample size, heterogeneous
patient population, or analysis based on PET imaging alone. In
published studies the final diagnosis was based mostly on
clinical or radiological follow-up after 6 – 24 months [3, 5,
7, 10–13, 16]. Only some studies used a reference standard
based on final pathology obtained in all patients [5]. The
Fig. 2 Adrenal metastasis from lung cancer. 18F-FDG PET/CT findings
in a 53-year-old man with lung cancer (a CTimage, b PET image, c fused
PET/CT image). The 18F-FDG PET/CT image shows increased uptake of
18F-FDG in a left adrenal tumour. The SUVmax of the tumour was 10.1
and the attenuation value 21 HU; the liver SUVmax was 3.1. The
histopathological diagnosis was metastasis from lung cancer
Fig. 3 Malignant transformation of adrenal angiomyolipoma. 18F-FDG
PET/CT findings in a 59-year-oldwomanwith an unknown primary cancer
(a CT image, b PET image, c fused PET/CT image). The 18F-FDG PET/
CT image shows increased 18F-FDG uptake in a left adrenal tumour. The
SUVmax of the tumour was 6.3 with attenuation values in the range −57 to
77 HU (mean 16 HU); the liver SUVmax was 3.6. This tumour was
classified correctly as malignant using semiquantitative data from 18F-
FDGPET/CT. The final histopathological diagnosis was adrenal malignant
transformation of angiomyolipoma
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earlier studies showed that the use of qualitative (visual) data
for characterizing adrenal tumours may be more helpful than
SUVmax or SUVmean. The authors of the largest study of the
quantitative and qualitative value of 18F-FDG PET/CT sug-
gested that qualitative analysis alone should suffice for differ-
entiation between benign and malignant adrenal tumours and
the routine use of SUVmean or SUVmax may be unnecessary
[11]. However, the quantitative criteria seem to be subjective
and to yield inconsistent results especially for borderline
cases. On the other hand critics of quantitative methods con-
tend that SUV measurements are variable due to the type of
ROI, partial volume effects and many other factors including
the patient’s body composition, plasma glucose level, image
noise and image reconstruction method used [3, 18].
Over the last several years, PET/CT techniques have
evolved resulting in more sensitive cameras. The combination
of higher resolution PETcameras, and new reconstruction and
correction algorithms used in the acquisition have provided
the required maximum image quality for precise SUV mea-
surements. Due to advances in technology quantitative analy-
sis with PET/CT has been recognized as providing an objec-
tive, more accurate, and less observer-dependent measure for
characterizing adrenal tumours than visual assessment alone
[6, 18, 19]. In published studies authors have suggested
adrenal SUVmax cut-off values of 2.3, 2.5, 2.7, 3.1, 3.4 and
3.9, but it has been well recognized that absolute adrenal
SUVmax or SUVmean threshold values that could reliably
differentiate all benign frommalignant adrenal tumours do not
exist [10–12, 15, 16, 20, 21]. The SUVmax cut-off >3.9
yielded a sensitivity of 96 % and a specificity of 82 % [15].
Recently the use of the T/L SUVmax ratio has been recom-
mended to improve the reproducibility and performance of 18F-
FDG PET/CT. The use of liver activity as internal control that
may enable monitoring of the reliability of SUVmeasurements
and in this way the effects of many external factors, can be
omitted [5, 15, 16]. Different T/L SUVmax ratio cut-off values
(1, 1.37, 1.45, 1.8) have been proposed for differentiating
benign from malignant tumours with good sensitivity but
weaker specificity [5, 7, 10, 11, 15, 16, 20]. In one study a
T/L SUV ratio >1.37 yielded a sensitivity of 96 % and speci-
ficity of 100 % and had a greater ability to differentiate benign
adenomas from adrenal metastases than SUVmax [15]. In
another study, the best correlation between 18F-FDG PET/CT
imaging and histological evaluation of adrenal tumours was
found using a T/L SUVmax ratio cut-off >1.0 [16]. This
threshold was more accurate in differentiating the tumour type
than SUVmax or visual interpretation alone, yielding a sensi-
tivity of 97 % and a specificity of 92 % [16]. Similarly, in our
Fig. 4 Phaeochromocytoma of the right adrenal gland. False-positive
18F-FDG PET/CT findings in a 38-year-old woman with lung
cancer (a CT image, b PET image, c fused PET/CT image). The 18F-
FDG PET/CT image shows increased uptake of 18F-FDG in a right
adrenal tumour. The SUVmax of the tumour was 8.4 and the attenuation
value 41 HU; the liver SUVmax was 3.0. The final histopathological
diagnosis was benign phaeochromocytoma
Fig. 5 Bilateral adrenal tuberculosis. False-positive 18F-FDG PET/CT
findings in a 62-year-old man with a history of lung cancer (a CT image,
b PETimage, c fused PET/CTimage). The 18F-FDGPET/CTimage shows
enlarged adrenal tumours with bilateral intense uptake of 18F-FDG. The
SUVmax of the left adrenal tumour was 12.1 and the attenuation value 33
HU, and the SUVmax value of the right adrenal tumour was 14.4 and the
attenuation value 29 HU; the liver SUVmax was 2.4. The final
histopathological diagnosis was bilateral adrenal tuberculosis
Eur J Nucl Med Mol Imaging (2014) 41:2273–2280 2277
study we found that 18F-FDG PET/CT was highly efficient in
distinguishing malignant from benign adrenal tumours. In our
series a T/L SUVmax ratio cut-off of 1.53 corresponded to a
sensitivity of 93.8 % and a specificity of 91.4 %, whereas an
adrenal SUVmax cut-off of 5.2 corresponded to a sensitivity of
90.6% and a specificity of 90%. In evaluating adrenal tumours
a T/L SUVmax ratio of 1.53 yielded high sensitivity, specific-
ity, NPV comparable to those using an adrenal SUVmax of 5.2.
Moreover, although the use of liver activity as an internal
control should correct for some of the variables that affect
SUV measurements, no significant differences in terms of
diagnostic accuracy were observed between the two parame-
ters, but T/L SUVmax ratio was found to be an independent
predictor of malignancy. In the ROC curve analysis tumour
diameter had the lowest AUC. The diagnostic threshold for a
diameter >30 mm yielded a sensitivity of 48.9 % and a spec-
ificity of 88.6 % so was a poor predictor of malignancy.
The major cause of false-positive results may vary among
studies. In previous studies false-positive 18F-FDG PET/CT
findings were mainly adrenal adenomas and benign
phaeochromocytomas. It has been suggested that the function-
al state of an adenoma could be a factor determining the
intensity of 18F-FDG metabolism, but others have found a
lack of correlation between hormonal hypersecretion and 18F-
FDG uptake. Several studies have shown that tuberculosis can
produce high 18F-FDG uptake and limit the specificity
of 18F-FDG PET/CT scans by mimicking metastases
[11, 12, 16, 22, 23].
The finding of our study confirm those of previous studies
that 18F-FDG accumulates in some benign adrenal masses. In
Fig. 6 ROC curve for the ability
of adrenal SUVmax to predict
malignancy
Fig. 7 ROC curve for the ability
of the T/L SUVmax ratio to
predict malignancy
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our series a T/L SUVmax ratio threshold of >1.53 yielded six
false-positive results: four adrenal tuberculosis and two be-
nign phaeochromocytomas. The benign lesions related to
tuberculosis showed a hypermetabolic pattern. In one patient
with bilateral adrenal tuberculosis, 18F-FDG- PET/CTshowed
low uptake of 18F-FDG, which could have been the result of a
lack of granulomatous inflammation due to the local suppres-
sive effect of steroids secreted in the adrenal cortex. Four
false-positive results underscore the necessity for keeping
adrenal tuberculosis in mind as a possible differential diagno-
sis in bilateral adrenal masses in regions where tuberculosis is
endemic. In previous studies, false-negative results have been
recognized because of a small lesion size (<8 mm), the low
18F-FDG avidity of certain cancer types (e.g. renal cell cancer,
neuroendocrine tumours, bronchoalveolar carcinoma), and
metastases with haemorrhage and/or necrosis [12, 14, 16,
24]. Some authors have speculated that false-negative adrenal
metastases might be the result of suppressive effects of prior
chemotherapy on tumour glucose metabolism [14, 16]. In this
study the T/L SUVmax ratio threshold of >1.53 yielded two
false-negative results for adrenal metastasis from colon carci-
noma and adrenal carcinoma with SUVmax 4.2 and 4.6 and
T/L SUVmax ratios 1 and 1.12, respectively. One of these
patients had a history of chemotherapy received 4 months
before examination, and the other had a large tumour with
necrosis.
Some studies have indicated that the accuracy of 18F-FDG
PET/CT might be improved by combining the PET parameters
with the attenuation value from the unenhanced CT scan [10, 12,
25]. In one study the use of a mean CT attenuation of >10 HU
combined with either of the PET criteria SUVmax >3.1 or T/L
SUV ratio >1.0 improved the performance of PET/CT in charac-
terizing adrenal tumours. A combined T/L SUVmax ratio of >3.1
and amean attenuation of >10HU had a sensitivity of 97.3% and
a specificity of 86.2 %, a combined T/L SUVmax ratio of >1.0
and amean attenuation of >10HU had a sensitivity of 97.3% and
a specificity of 74.1 %. The accuracies of these threshold combi-
nations (90.5 % and 83.2 %, respectively) were significantly
different. [10]. In another recent study showed better sensitivity
and accuracy with a combined T/L SUVmax ratio of >1.3 and
HU >18. The sensitivity, specificity and accuracy of this method
for predicting malignancy were 97.7 %, 81.2 % and 93.4 %,
respectively [25].
It has been reported that lipid-rich adenoma may be differ-
entiated from lipid-poor adenoma and metastasis using a cut-
off value of 10 HU on unenhanced CT images. However,
limitations of this method have been reported in oncology
patients. Some authors found that unenhanced CT has a low
specificity and sensitivity, which leads to false-positive and
false-negative results. Based on a threshold of >10 HU, CT
misdiagnosed 21 % of true adenomas as metastases and
misdiagnosed 11 % of metastases as adenomas [26]. In our
study, a CT threshold of 10 HU for differentiating adrenal
tumours had a sensitivity of 93.8 %, a specificity of 67.1 %, a
PPVof 56.6 % and a NPVof 95.9 %.
In the multivariate analysis including adrenal
SUVmax, T/L SUVmax ratio, CT attenuation value
and tumour diameter categorized according to the
established cut-off values as predictors only T/L
SUVmax ratio was a predictor of malignancy. In con-
trast to previously published data, combined T/L
SUVmax ratio and HU attenuation value from
unenhanced CT images did not improve the characteri-
zation of adrenal tumours in our series. Only the T/L
SUVmax ratio was found to be an independent predictor
of malignancy.
It is well recognized that selection of the reference standard
is critical for the validity of a study of a test’s accuracy and the
definition of the diagnostic threshold forms part of the refer-
ence standard. The majority of published studies have mainly
been based on imperfect reference standards such as assessing
the change in tumour size over a follow-up of 6 – 24 months
[3, 10–14]. Errors resulting from the use of an imperfect
reference standard translate into poorer accuracy in the eval-
uation of a test’s diagnostic performance.
To the best of our knowledge, this is the second
largest study with histology confirmation comparing
the ability of 18F-FDG PET/CT to characterize adrenal
lesions. However the study had some limitations. First,
the study was retrospective and there was unavoidable
selection bias. The second limitation was the small and
heterogeneous sample size: patients had a variety of
different malignancies and therapy regimens.
Conclusion
Based on our results the use of quantitative parameters of
18F-FDG PET/CT led to high sensitivity, specificity and
NPV in diagnosing adrenal tumours in oncological pa-
tients. Diagnostic accuracies of adrenal SUVmax and T/L
SUVmax ratio were comparable, but T/L SUVmax ratio
was an independent predictor of malignancy. Further large
multicentre prospective studies based on histology as the
reference standard are needed to confirm our results and
determine whether they can be applied to healthy patients
with adrenal incidentalomas.
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